AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

(Reuters) -AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Tasim Zahid)